Joachim Stangier
Biberach An Der Riss, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
Journal: Journal of thrombosis and haemostasis : JTH
Published: October 11, 2018
Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials.
Journal: Thrombosis and haemostasis
Published: August 17, 2018
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
Journal: The New England journal of medicine
Published: July 12, 2017
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study.
Journal: Research and practice in thrombosis and haemostasis
Published: February 26, 2017
Authors' Reply to Kamel et al.: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".
Journal: Clinical pharmacokinetics
Published: December 29, 2016
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
Journal: The American journal of emergency medicine
Published: October 07, 2016
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Journal: The American journal of medicine
Published: August 30, 2016
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
Journal: British journal of clinical pharmacology
Published: July 29, 2016
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
Journal: Clinical pharmacokinetics
Published: June 19, 2016
Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers.
Journal: Thrombosis and haemostasis
Published: May 19, 2016
Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers.
Journal: Journal of the American College of Cardiology
Published: October 29, 2015
Last Updated: 09/26/2026